mBIOTA Elemental
Commercial- Indications
- Small intestinal bacterial overgrowth, Irritable bowel syndrome, Crohn's disease
Company intelligence / Profile preview
mBIOTA Labs’ flagship product, mBIOTA Elemental™, demonstrated 100% SIBO eradication in SIBO-only patients and 73% overall SIBO/IMO eradication after two weeks in its first prospective clinical trial at Cedars-Sinai. The study also showed 100% patient compliance. Additional data show significant reduction or elimination of Methanobrevibacter smithii in IMO patients after two weeks. The diet is clinically proven to be effective and highly palatable, addressing historic compliance issues with elemental diets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on mBIOTA Labs.